Quanticate upgrades pharmacovigilance database

By Melissa Fassbender contact

- Last updated on GMT

Quanticate is a global CRO focused on the management, analysis, and reporting of data from clinical trials and post-marketing surveillance. (Image: iStock/PRImageFactory)
Quanticate is a global CRO focused on the management, analysis, and reporting of data from clinical trials and post-marketing surveillance. (Image: iStock/PRImageFactory)

Related tags: Clinical research

The data-focused clinical research organization (CRO) Quanticate has upgraded its pharmacovigilance safety database ahead of EudraVigilance’s go-live in November.

Quanticate has updated safety data management and global safety database to the latest version of Oracle Argus​, v8,1.

According to the UK-based CRO, the investment anticipates the launch of an improved version of EudraVigilance – the European Medicines Agency’s (EMA) system for managing and analyzing information on suspected adverse reactions to medicines.

Compliant with Article 2(3) of Directive 2010/84/EU2, adverse reactions must be submitted electronically to the EudraVigilance database.

Per the EMA’s website​, the new version of EudraVigilance “is fully functional and ready to ​go live on 22 November 2017​.”

The enhancement of EudraVigilance follows the revised EU legislation on pharmacovigilance, which updated the legal framework for reporting and analysing suspected adverse reactions to improve health protection​,” according to the EMA.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars